---
schema_version: "secwatch.filing_event.v1"
accession: "0001213900-25-061939"
form_type: "8-K"
ticker: "PHGE"
cik: "0001739174"
company_name: "BiomX Inc."
filed_at: "2025-07-08T23:59:59+00:00"
generated_at: "2026-05-18T09:07:10.261648+00:00"
event_type: "other_material"
sentiment: "positive"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# BiomX publishes Phase 1b/2a BX004 data in Nature Communications; shows 500-fold bacterial reduction

## Summary
- BX004 achieved 2.7 log10 (~500-fold) greater bacterial reduction vs placebo in CF patients with chronic P. aeruginosa infections.
- No bacterial resistance to BX004 emerged during the trial, addressing a key limitation of antibiotics.
- Phase 2b trial of BX004 initiated; topline results expected Q1 2026.
- BX004 was safe and well-tolerated with no treatment-related safety events across all patients and dose levels.
- Therapeutic phages were detected at infection site up to one week after end of therapy.

## SEC filing metadata
- accession: 0001213900-25-061939
- form_type: 8-K
- ticker: PHGE
- cik: 0001739174
- company_name: BiomX Inc.
- filed_at: 2025-07-08T23:59:59+00:00
- event_type: other_material
- sentiment: positive
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1739174/000121390025061939/0001213900-25-061939-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1739174/000121390025061939/ea0248257-8k_biomx.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001213900-25-061939
- JSON: https://secwatch.observer/filing/0001213900-25-061939.json
- Plain text: https://secwatch.observer/filing/0001213900-25-061939.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.